CPRX EBITDA Margin
Catalyst Pharmaceuticals Inc · EBITDA Margin
CPRX EBITDA Margin
Latest reported56.06%period ending
CPRX TTM EBITDA Margin (2907.08% → 56.06%)
TTM ebitda margin
High-resolution chart · PNG
CPRX ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| 56.0582% | |
| 54.566% | |
| 55.9653% | |
| 55.469% | |
| 55.4131% | |
| 51.6615% | |
| 49.1329% | |
| 30.0142% | |
| 29.7226% | |
| 32.0582% | |
| 30.2618% | |
| 53.203% | |
| 51.6134% | |
| 49.4662% | |
| 44.4218% | |
| 42.6621% | |
| 39.2754% | |
| 37.4756% | |
| 36.3799% | |
| 36.4158% | |
| 34.3356% | |
| 35.3817% | |
| 35.3344% | |
| 36.9649% | |
| 37.5779% | |
| 32.2217% | |
| 13.5606% | |
| -30.0626% | |
| -234.0497% | |
| -7,051.4374% | |
| -969.1115% | |
| -923.8464% | |
| -913.6963% | |
| -817.7471% | |
| 2,404.4361% | |
| 3,274.1469% | |
| 3,812.3073% | |
| 4,042.7664% | |
| 6,034.6974% | |
| 4,563.1879% | |
| 3,474.3903% | |
| 2,907.0819% |